One Day MD | Evidence-Based Wellness

A practical 2026 guide to comparing online peptide and GLP-1 care, with a focus on prescription legitimacy, FDA approval, compounding, clinician oversight, pharmacy sourcing, cost and patient safety. Last updated: October 2, 2026 Scope of this guide: This article primarily examines the U.S. telehealth market because FDA approval and U.S. compounding rules are central to the current peptide landscape. Availability, prescribing rules and product registration differ substantially in other countries. Telehealth has changed how patients access peptide-based medicines. Instead of starting with a traditional clinic visit, patients can often complete an online health assessment, meet a clinician by video or messaging, receive a prescription when medically appropriate, and have medication delivered through a pharmacy. The problem is that the word “peptide” now covers very different categories of products. An FDA-approved prescripti...

By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: October 2026 Quick Answer: One Day MD is an independent, evidence-based health library covering supplements, longevity, GLP-1 and weight management, cancer prevention, heart and metabolic health, brain and sleep, immunity, skin, joints, family health and finding a specialist. Use this page as your map: check the date, pick a pillar, then narrow by label. Disclosure: Some pages link to products or partners, and we may earn a commission at no cost to you. This is educational content, not medical advice. In This Guide How to Use This Site Topic Index (12 pillars) Site Tools and Sister Sites AI Personalization Guide FAQ How to Use This Site 1 Check the date : Look for the Last updated line. 2026 guides use current evidence; older posts may not. 2 Pick a pillar : Match your question to one of the 12 pillars below and read its flagship guides first. 3 Narrow by label : Labels list every post on a topi...

Updated October 2, 2026 Semaglutide and tirzepatide can produce substantial weight loss, but an important question has emerged alongside the popularity of GLP-1-based obesity medicines: How much of the weight lost is fat, and how much is lean mass? The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both drugs reduce fat mass and also reduce lean mass during weight loss. However, lean mass is not synonymous with skeletal muscle , and results from separate trials cannot be interpreted as a direct head-to-head comparison of muscle preservation. A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass accounted for approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide . However, the authors did not establish that tirzepatide preserves functional skeletal muscle better than semaglutide. The analysis also found that ad...